Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lifted its position in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 1.7% during the third quarter, HoldingsChannel.com reports. The fund owned 108,799 shares of the biotechnology company’s stock after acquiring an additional 1,794 shares during the period. Segall Bryant & Hamill LLC’s holdings in Anika Therapeutics were worth $2,687,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Eastern Bank acquired a new stake in Anika Therapeutics during the 3rd quarter worth $28,000. Quest Partners LLC lifted its stake in shares of Anika Therapeutics by 115.8% in the third quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock worth $171,000 after buying an additional 3,705 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Anika Therapeutics during the first quarter worth about $180,000. State Board of Administration of Florida Retirement System purchased a new stake in Anika Therapeutics during the 1st quarter valued at about $198,000. Finally, Atria Investments Inc acquired a new stake in Anika Therapeutics in the 3rd quarter valued at about $218,000. 91.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ANIK. Barrington Research lowered their target price on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. StockNews.com cut Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, November 4th.

Anika Therapeutics Price Performance

Shares of ANIK stock opened at $16.97 on Friday. The company has a market capitalization of $248.61 million, a PE ratio of -2.62 and a beta of 0.86. The firm’s 50-day moving average is $22.38 and its two-hundred day moving average is $24.76. Anika Therapeutics, Inc. has a 12 month low of $16.00 and a 12 month high of $29.11.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.